Kymera Therapeutics Inc. (NASDAQ: KYMR) presented phase 1 study results for its experimental drug KT-621 in healthy Japanese adults at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE